Students for Life Gives FDA 60 Days to Act on Mifepristone Under Endangered Species Act
核心洞察
Students for Life of America (搜索) filed a notice of intent to sue the FDA, alleging the agency approved mifepristone in 2000 without required wildlife consultations under the Endangered Species Act.
The 60-day notice window runs to about Nov. 23, after which the group says it will file suit in federal court if the FDA does not act.
The FDA rejected the same legal argument on Jan. 15, 2025, and the cited water studies detected anti-progesterone activity rather than mifepristone itself.
Students for Life of America (搜索) formally warned the Food and Drug Administration (搜索) on Sept. 24 that it will sue under the Endangered Species Act unless the agency acts on the abortion pill mifepristone within 60 days. The group argues the FDA broke federal wildlife law when it approved the drug in 2000 without consulting the U.S. Fish and Wildlife Service or the National Marine Fisheries Service.
The notice asks the FDA to take specific actions, including environmental testing and pulling the drug from the market. The 60-day window, which the wildlife law requires before most citizen lawsuits, runs to about Nov. 23. The notice was filed hours before Dr. Heidi Overton, President Trump's nominee to lead the FDA, appeared for her Senate confirmation hearing.
For patients, nothing changes. Mifepristone remains available under current FDA rules, including by mail, after the Supreme Court preserved access to the drug in May while Louisiana's legal challenge continues. Medication abortions accounted for nearly two-thirds of U.S. abortions in 2023, the most recent year with national data.
The Legal Theory Behind the Notice
The Endangered Species Act requires federal agencies to consult wildlife regulators when an action may affect protected species or their habitats. Students for Life says the FDA skipped that step when it approved mifepristone and when it later allowed prescribing by telemedicine and delivery by mail. The group says it filed 11 citizen petitions before this notice.
The FDA has already rejected the argument once. On Jan. 15, 2025, the agency answered one petition by saying it was not required to consult wildlife agencies before approving the drug.
"We expect these environmental concerns to be taken seriously," Students for Life President Kristan Hawkins told Fox News, adding that otherwise the group expects to see the FDA in court. She also pitched the issue beyond abortion politics: "But we all want clean drinking water."
In the letter, sent to Health and Human Services Secretary Robert F. Kennedy Jr., acting FDA Commissioner Kyle Diamantas and acting Center for Drug Evaluation and Research Director Michael Davis, the group states that the FDA is "in violation of Section 7 of the ESA for failing to engage in consultation with the Services in connection with approving mifepristone and issuing REMS for it." The group says it is seeking to prevent the "dumping of mifepristone into the waterways of the United States."
Kristi Hamrick, the group's vice president of media and policy, told the Daily Signal that the legal standard is risk, not proven harm: "As a matter of law, we don't have to show harm to endangered species, we need to show risk." The group says more than 1,500 protected species live in all 50 states and that it named some of those species, including freshwater mussels such as the Balcones spike, Texas fawnsfoot, fatmucket and pimpleback, in the notice. It also says it circulated a broader list to state attorneys general.
The group claims more than 50 tons of blood and placental tissue contaminated with mifepristone are expelled into U.S. waterways each year. Environmental scientists dispute that claim, according to The Hill.
A notice of intent has no legal effect on its own. It does not alter the drug's approval, its label, or how pharmacies and telehealth services dispense it.
A Closer Look at the Water Evidence
The science offered so far is thin. Of six studies cited in the notice, four did not examine whether mifepristone was present in environmental water samples.
The newest paper, published in Issues in Law & Medicine, a journal of the Alliance for Hippocratic Medicine, reported anti-progesterone activity in water samples from three U.S. cities: Austin, Texas; Blacksburg, Virginia; and Carbondale, Illinois, including household taps. The study found anti-progesterone activity consistent with mifepristone in 8 of 9 sampling classes, with concentrations reaching 0.041 micrograms per liter, and concluded that conventional treatment did not reliably remove the contaminant.
That kind of test detects a biological effect, not the drug itself. The researchers said another compound could have produced the same result, and confirming mifepristone would generally require a chemistry method that identifies the specific molecule. In plain terms, the evidence shows a possible signal in a small number of samples. It does not show that mifepristone is in tap water, at what level, or that any level found harms people or wildlife. The notice is a legal claim, not a regulatory finding, and no court has ruled on it.
Hawkins told Fox News Digital that the notice does not rest on a single study but on "the failure of the FDA in 2000 to literally follow the law."
Overton Hearing Puts the FDA's Next Move in Focus
At her hearing before the Senate health committee, Overton said mifepristone "has met the safety and efficacy determinations of the FDA," but she would not say how she would handle the drug if confirmed. Asked by Sen. Tammy Baldwin, D-Wis., whether its label should change, she pointed to the agency's ongoing internal safety review. "I can't prejudge the determination of a safety review that is currently ongoing," Overton said, according to Fierce Healthcare.
The FDA's review has been underway since 2025, and initial results are expected within weeks. While at the America First Policy Institute, Overton wrote that the FDA's decision to allow mail delivery of mifepristone was "dangerous to women," PBS NewsHour reported.
The people most affected by any future change include those seeking a medication abortion, patients who rely on telehealth because the nearest clinic is far away, and people managing a miscarriage (搜索), for whom mifepristone is also used.
Patients with a current prescription should follow their clinician's instructions and should not change their care because of this notice. Warning signs that need prompt attention include very heavy bleeding, a fever that does not go away, and severe abdominal pain. Anyone with those symptoms should contact a clinician right away or seek emergency care.
The FDA can respond within the 60-day window or let it pass. If the agency does not act, Students for Life says it will file suit in federal court. For now, this is a legal warning, not a ruling, and access is unchanged.